From prediction to precision: how immunopeptidomics advances neoantigen discovery
Trends in Cancer · 2026-06 · 12 (6) · 527-541
DOI: 10.1016/j.trecan.2026.02.003 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Trends in Cancer, 2026-06. Verfasst von Ilja E Shapiro und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, University of Lausanne (UNIL) and Lausanne University Hospital (CHUV), Lausanne, Vaud, Switzerland; Ludwig Institute for Canc…. Hauptthemen laut MEDLINE: Antigens, Neoplasm, Neoplasms, Peptides. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 134 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ludwig Institute for Cancer Research Ltd, Swiss Bridge Foundation, Cancer Research Foundation Switzerland.
Abstract (Originalsprache)
T cell recognition of peptides presented by class I and II human leukocyte antigen (HLA) molecules is fundamental to cancer immunity and personalized immunotherapy. Neoantigens, peptides containing somatic mutations, are attractive therapeutic targets due to their tumor specificity and immunogenicity. Current neoantigen discovery pipelines rely on sequencing and computational predictions but often struggle to identify peptides that are both presented and immunogenic. Immunopeptidomics, which uses mass spectrometry to identify naturally presented HLA-bound peptides, enables detection of neoantigens displayed on tumor cells. This review explores how immunopeptidomics complements existing tools to refine neoantigen identification, improves machine learning prediction algorithms through immunopeptidomics-derived datasets, and distinguishes between mutant and wild-type immunopeptides. We also highlight emerging developments that will further integrate immunopeptidomics into personalized immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, University of Lausanne (UNIL) and Lausanne University Hospital (CHUV), Lausanne, Vaud, Switzerland; Ludwig Institute for Cancer Research, Lausanne Branch, Lausanne, Vaud, Switzerland; Agora Cance…
Förderung
- Ludwig Institute for Cancer Research Ltd
- Swiss Bridge Foundation
- Cancer Research Foundation Switzerland
Zitieren
APA
Shapiro, I. E., & Bassani-Sternberg, M. (2026). From prediction to precision: how immunopeptidomics advances neoantigen discovery. Trends in Cancer, 12(6), 527-541. https://doi.org/10.1016/j.trecan.2026.02.003
Vancouver
Shapiro IE, Bassani-Sternberg M. From prediction to precision: how immunopeptidomics advances neoantigen discovery. Trends in Cancer. 2026;12(6):527-541. doi:10.1016/j.trecan.2026.02.003
BibTeX
@article{Shapiro2026,
author = {Shapiro, Ilja E and Bassani-Sternberg, Michal},
title = {From prediction to precision: how immunopeptidomics advances neoantigen discovery},
journal = {Trends in Cancer},
year = {2026},
volume = {12},
number = {6},
pages = {527--541},
doi = {10.1016/j.trecan.2026.02.003}
}
EUVIMED